Invented names for medicines in the EU: how they are assessed and why they are rejected

Every medicine authorised in the EU needs a name, and most companies want an invented one. That name is checked as a safety matter: by EMA's Name Review Group for centralised products, and by each national agency in national, mutual recognition and decentralised procedures.

Read more about what this guide covers

A name that looks or sounds like an authorised product, borrows from an INN, promises too much or means something unfortunate in one language comes back with an objection, and a late objection can leave a launch without its brand. This guide sets out the legal basis, how the Name Review Group procedure runs and when to use it, the criteria that decide acceptability, how national agencies differ, why a registered trade mark is not enough, and how to screen a shortlist before an assessor does.

16 min readUpdated 8 primary sources

Reviewed by Gosia Luksza, CEO at Regunaut

Key figures
Earliest a name request can be made before the planned application
18 months
Maximum accepted per application, fully or conditionally
2 names
Validity of an accepted name from CHMP adoption, extendable once by one year
3 years
Time national authorities have to raise objections once consulted
30 days

In short

  • The name is part of the marketing authorisation and is assessed for patient safety, so a registered trade mark does not make a name acceptable.
  • For centralised products the Name Review Group accepts at most two names per application, at the earliest 18 months before submission, and an accepted name is valid for three years.
  • Objections are raised on similarity to another medicine's name in print, speech or handwriting, on INN and INN-stem conflicts, on misleading or promotional connotations and on unsuitable qualifiers.
  • In MRP, DCP and national procedures each agency applies its own naming guidance, so one name has to pass every Member State where it will be used.

Each section opens with its main point. Open the ones you need.

What the law means by the name of a medicine

Article 1(20) of Directive 2001/83/EC defines the name of the medicinal product as a name which 'may be either an invented name not liable to confusion with the common name, or a common name or scientific name accompanied by a trade mark or the name of the marketing authorisation holder'. Article 1(21) defines the common name as the international non-proprietary name (INN) recommended by the World Health Organization or, if one does not exist, the usual common name. An applicant therefore has two lawful constructions: an invented name, or the INN followed by the company name or a trade mark. Nothing obliges a company to invent a name, but most do.

Read more about What the law means by the name of a medicine

The name is part of the authorisation. It opens section 1 of the summary of product characteristics, appears on the labelling and in the package leaflet, and cannot be changed without a variation. Because it is how prescribers, pharmacists and patients pick the product, regulators assess it as a medication-error risk.

For the centralised procedure, Article 6 of Regulation (EC) No 726/2004 adds a rule of its own: each application, 'otherwise than in exceptional cases relating to the application of the law on trade marks, shall include the use of a single name for the medicinal product'. One Commission decision, one name, in every Member State.

The single-name exception is narrow

Where the proposed trade mark has been cancelled, opposed or objected to under trade mark law in a Member State, the Commission may accept a second name for that Member State. The holder has to show evidence of its failed efforts and obtain the derogation in writing, and the second name may not be used to partition the EU market.

EMA's Name Review Group: who decides for centralised products

For centralised products the check is done by the (Invented) Name Review Group, the NRG, which the Committee for Medicinal Products for Human Use (CHMP) set up to review names before authorisation. It is composed of representatives of the Member States and chaired by an EMA representative. The European Commission takes part, and other experts, such as from the WHO, are consulted case by case. Its conclusions go to the CHMP for adoption.

Its rulebook is the Guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014). Revision 7 was adopted by the CHMP on 4 December 2023 and has applied since 1 January 2024. It clarified the tests for misleading connotations and the 50% rule for similarity to INNs, defined umbrella branding and cognitive error, and formalised conditional acceptance of names.

When to submit a name request, and how the review runs

A request can be made once the CHMP has confirmed that the product is eligible for the centralised procedure, at the earliest 18 months before the planned submission of the marketing authorisation application. EMA's pre-authorisation guidance recommends four to six months before submission. The request goes to the NRG secretariat on the name request form, with a draft SmPC or a product profile and any supporting material, such as a justification for a qualifier or the applicant's own similarity research.

  1. Step 1

    Submit by the published deadline

    The NRG holds five plenary meetings in 2026 and five in 2027, each with a submission deadline some six weeks earlier. For 2027 EMA caps new invented names at 85 per meeting, first come, first served, and defers requests that do not fit. Up to two names can be proposed per meeting, in order of preference.

  2. Step 2

    EMA similarity analysis

    EMA compares each proposal with the names in the public Article 57 product data and in the NRG's own database, which includes confidential names proposed for products not yet authorised, and passes the similar pairs to the national authorities.

  3. Step 3

    Consultation of the Member States

    Each national authority checks the names against its own databases and in its own language, and has 30 days to object.

  4. Step 4

    NRG discussion

    Similarity objections go through a four-step checklist: degree of similarity in print, speech and handwriting; setting of use; factors that increase or reduce the risk; and potential for harm in a mix-up. The later steps apply only when similarity is medium or high.

  5. Step 5

    CHMP adoption and outcome letter

    The CHMP adopts the conclusions three to five weeks after the NRG meeting in the 2026 calendar, nine to fourteen weeks after the submission deadline. The NRG chair then sends the outcome with the reasons for any objection.

  6. Step 6

    Choose the name

    No later than one month before the CHMP opinion on the application, the applicant tells EMA and the NRG secretariat which accepted name it will use.

An accepted name is valid for three years from CHMP adoption and can be reconfirmed once, for one more year, before it expires. Once the application is validated the name counts as 'in use' and does not expire during the procedure. Acceptance is tied to the product profile the NRG saw: a change of indication, route, strength or pharmaceutical form has to be notified, because it can change the similarity assessment.

The application can be filed without an accepted name

If no invented name has been accepted by submission, the application can be filed under one of the proposed names or under the INN with the company name. If none is accepted by the time of the opinion, the opinion is adopted under the common name with the name of the holder. That construction is not a default: it also needs NRG endorsement. An invented name can be added later by variation.

The acceptability criteria

Section 4 of the guideline groups the criteria under safety and public health concerns, INN concerns and product-specific concerns. The table summarises the main ones.

Main acceptability criteria for invented names under the EMA guideline
CriterionWhat the NRG looks atWhat to avoid
Confusion with another medicineSimilarity in print, speech and handwriting with the names of authorised, suspended and withdrawn products in any Member State, whatever the authorisation route, and with names accepted for pending applications. Indication, population, form, route, strength, setting and legal status are weighed against the potential for harm.Shared prefixes, infixes or suffixes, the same first and last letters, similar length and syllable count, and a name that contains another product's full invented name.
Withdrawn productsA name close to that of a product with no valid authorisation left in the EU and EEA is in principle still a conflict for five years after the authorisation ended, unless the applicant shows that the sell-off period is over.Assuming a name is free because the product has left the market.
Misleading connotationElements that allude to the indication, the mechanism of action, the composition, the pharmaceutical form or the route, and would be inaccurate now or after a later change to the product.Fragments tied to one indication, form or ingredient when others may follow.
Promotional messageA name that is overly fanciful, implies unique effectiveness or superiority, overstates efficacy, minimises risk, broadens the indication or trivialises use.Superlatives and claims hidden in syllables.
Pronunciation and readabilityDifficulty of pronunciation in the official EU languages, and identification in electronic systems.Consecutive vowels or consonants, especially at the start; very short names; names too long for small containers.
Meaning and formOffensive or inappropriate connotation in any official EU or EEA language, and whether the name is a word at all.Checking only the languages the team speaks; names made up wholly of initials or code numbers; punctuation marks.

Similarity is not judged on spelling alone. The guideline recognises cognitive error: two names that do not share the same letters in the same order can still be confused because of how they are perceived. National authorities add the phonetic side, since the same letters are pronounced differently across languages.

Pack design counts too. The way a name is displayed can increase its similarity to another name, and the point returns at the review of mock-ups during the assessment.

INNs and INN stems in invented names

Article 1(20) requires that an invented name is not liable to confusion with the common name. The NRG applies this together with World Health Assembly resolution WHA46.19, which asks that invented names are not derived from INNs and that INN stems are not used in them. WHO's guidance on INNs puts it more bluntly: trade marks cannot be derived from INNs and must not include their common stems.

Read more about INNs and INN stems in invented names

Stems are the shared syllables that mark a pharmacological group, such as -pril for ACE inhibitors or -tide for peptides, and WHO publishes them in its stem book with periodic addenda. The NRG checks whether the proposed name is too close to the product's own INN or to another INN, and whether it contains a stem. It uses a 50% rule to support the decision: it looks for cases where half or more of the invented name is made up of INN parts, or half or more of the INN appears in the invented name, then considers the letter strings shared, their sequence and their position.

Where the applicant uses the INN with a company name or trade mark instead of an invented name, as many generics do, the guideline sets rules of construction.

  • The INN recommended by WHO is used exactly as published, without omissions or abbreviations. A published modified INN (INNM) is used in the same way.
  • The company element corresponds to all or part of the holder's official name. An acronym is acceptable only if it is a registered company trade mark that identifies the holder.
  • There is no punctuation between the INN and the company name. In a fixed combination the INNs are separated by a forward slash.

Qualifiers, abbreviations and umbrella names

A qualifier is a group of letters or a word added after the invented name, separated from it by a space, to distinguish a presentation. The guideline accepts qualifiers in principle, with an explanation in every case, and weighs the information they give against the risk of a more complex name. A qualifier should say something about the product, such as duration of action, a device or the patient population, and should work in every language without translation. Symbols, dose designations and prescribing abbreviations are to be avoided, and a qualifier made of a single letter or of numbers is discouraged because it can be read as a strength or a dose.

Read more about Qualifiers, abbreviations and umbrella names

Adding a qualifier to a name already in use creates a different name, which for a centralised product means a new application.

Umbrella branding is the use of a common segment, for example part of the sponsor's name, across the invented names of different medicines. As a general principle the NRG does not accept it, because the link between the products can lead to confusion and medication errors. A segment may pass in a first name if it is not significant and evident in the name as a whole, but not in a second. For non-prescription medicines the guideline allows names that are informative without being promotional.

National rules on umbrella brands can be stricter

France's ANSM, in its 2018 recommendations on medicine names, does not accept one invented name across several non-prescription medicines of the same holder with different active substances and indications, and opposes a medicine sharing all or part of its name with a medical device, a cosmetic or a food product. A range name accepted in one country can be refused in the next.

National, MRP and DCP products: one name, many rulebooks

The single-name rule and the NRG belong to the centralised procedure. In a national procedure, a decentralised procedure or mutual recognition, each Member State grants its own authorisation and approves the name itself, under national law and its own guidance. The reference Member State leads the scientific assessment but does not settle the name for the others. A product can therefore carry different names in different countries, and a company that wants one name needs it to pass every agency concerned.

Read more about National, MRP and DCP products: one name, many rulebooks

National guidance follows the same principles as the EMA guideline, with local additions. The Norwegian Medical Products Agency's guidance on names for medicinal products covers MRP, DCP and national products and states that it is based on the EMA guideline. It adds that the name should be easy to pronounce in Norwegian and that an invented name should generally share no more than half the syllables of the INN. France's ANSM and Germany's BfArM and Paul-Ehrlich-Institut publish their own. The differences that matter in practice are these.

  • Language. Each agency checks pronunciation and meaning in its own language.
  • Local register. The comparison is with every name on the national register, including products authorised only in that country and names that have been withdrawn.
  • Qualifiers and range names. Tolerance for qualifiers and umbrella brands differs, especially for non-prescription medicines.
  • Process. There is no single advance check comparable to the NRG; each agency assesses the name under its own process.

A registered trade mark is not an accepted name

Trade mark offices and medicines regulators ask different questions. A trade mark office examines whether a sign can distinguish one undertaking's goods from another's and whether earlier rights stand in the way. A regulator asks whether a pharmacist could dispense the wrong product. EMA's guideline is explicit that the review of trade marks is outside its remit, that trade mark registration plays no part in its assessment, and that the applicant alone is responsible for trade mark clearance.

The two tracks fail independently. A name can be registered as an EU trade mark and be refused by the NRG because it resembles a product authorised in one Member State, and a name accepted by the NRG can still be opposed by the owner of an earlier mark. Pharmaceutical marks sit in class 5 of the Nice Classification, and a search there shows earlier marks, not authorised medicines. A shortlist has to clear both, and the regulatory clearance has to cover what no trade mark search will find, such as withdrawn products and INN stems.

How to screen a shortlist before filing

EMA asks applicants to apply the criteria themselves before submitting, and the NRG may limit its review when the number of objections shows that a name was poorly researched. It names the public data from the Article 57 database as the resource to use. The sequence below puts the checks in the order in which they eliminate candidates.

  1. Step 1

    Fix the product profile

    Write down the INN, indication, population, form, strength, route and legal status, and the procedures and Member States you will file in. Similarity is assessed against this profile, and the route decides which rulebooks and registers apply.

  2. Step 2

    Check the INN and stems

    Compare each candidate with the product's own INN and with other INNs, apply the 50% rule in both directions, and look for WHO stems anywhere in the invented segment.

  3. Step 3

    Search the registers

    Compare each candidate with authorised, suspended and withdrawn names in the Article 57 public data, the Union Register and the national registers of the countries concerned, in print, sound and handwriting.

  4. Step 4

    Read it in every language

    Check pronunciation, meaning and connotation in the official EU and EEA languages, or at least in those of the Member States concerned.

  5. Step 5

    Test the construction

    Look for promotional or misleading fragments, punctuation, qualifiers that read as a dose, and segments shared with the company's other products.

  6. Step 6

    Clear the trade marks

    Search earlier marks in class 5 at the EUIPO and the national offices concerned. This runs in parallel with the regulatory checks and does not replace them.

  7. Step 7

    Rank, keep a reserve and document

    Carry at least two surviving names in order of preference and keep the evidence, which becomes the supporting material for the request and for any justification.

Common reasons for rejection, and what to do after an objection

Objections map directly onto the criteria. The patterns below are the ones the guideline itself warns about.

Read more about Common reasons for rejection, and what to do after an objection
  • A near-identical name on one national register, for a product authorised in a single Member State.
  • A name close to that of a product whose authorisation ended less than five years ago.
  • An INN stem inside the invented segment, or a name that shares half its letters with an INN.
  • A fragment that points to an indication, a mechanism, a form or a strength.
  • A meaning, or a consonant cluster that is hard to pronounce, in one language.
  • A qualifier of a single letter or number, or a segment shared with the company's other products.
  • A conflict with a confidential name proposed by another applicant, which no public search can reveal.

The last case leads to conditional acceptance. Where the only similarity objection is with the name of a pending application, the name is accepted conditionally and can be used, but only the product authorised first keeps its name. Either applicant can ask the NRG secretariat to open a bilateral negotiation; both must consent before EMA discloses the names and the companies, and the two applicants then settle the matter between themselves.

After a rejection the applicant has three options under the guideline.

  • Propose new names, up to two per meeting, as long as the number accepted for the application does not exceed two.
  • Justify the rejected name on the justification form, addressing every objection and including an assessment of the potential for harm in a mix-up. The justification goes back to all Member States, and those that objected are asked to reconsider.
  • Proceed under the common name with the name of the holder and add an invented name later by variation, once the NRG has accepted one.

A justification works when it brings something the NRG did not have, such as the dispensing setting or a difference in form or route that makes a mix-up implausible; repeating that the two names are spelled differently does not address the checklist. Exceptionally, when all other means have been exhausted, the applicant may ask for the matter to be put to the CHMP during the evaluation of the product. The name also stays under review after authorisation: medication errors linked to the name of a centrally authorised product are to be notified to the NRG, and an objection can be raised at any time.

Put this guide to work

The jobs in the Regunaut platform that apply what this guide covers to your own product.

Terms used in this guide

Common questions

Invented names: what teams ask

What is an invented name for a medicine?

It is the brand name under which a medicine is authorised. Article 1(20) of Directive 2001/83/EC allows the name of a medicinal product to be either an invented name not liable to confusion with the common name, or the common or scientific name accompanied by a trade mark or the name of the marketing authorisation holder. The common name is the INN recommended by the WHO or, if none exists, the usual common name.

When should we submit a name to the EMA Name Review Group?

Once the CHMP has confirmed that the product is eligible for the centralised procedure, and at the earliest 18 months before the planned submission of the application. EMA recommends four to six months before submission. Requests are reviewed at five plenary meetings a year, each with a published submission deadline, and the outcome follows CHMP adoption a few weeks after the meeting.

How many names can be accepted, and how long does acceptance last?

Up to two names can be accepted per marketing authorisation application, fully or conditionally, and up to two can be proposed at each meeting. An accepted name is valid for three years from CHMP adoption and can be reconfirmed once for a further year. Once the application has been validated the name is 'in use' and does not expire during the procedure.

Can an invented name contain an INN stem?

It should not. World Health Assembly resolution WHA46.19 asks that invented names are not derived from INNs and do not use INN stems, and the Name Review Group reviews names on that basis. It checks for stems in the invented name and applies a 50% rule to similarity with INNs, looking at the shared letter strings, their sequence and their position, and decides case by case.

Is a registered trade mark enough to use a name for a medicine?

No. EMA does not take trade mark registration into account when it assesses a name, and the review of trade marks is outside its remit. A registered mark can be refused as a medicine name because it resembles an authorised product, contains an INN stem or is misleading. A name accepted by the regulator can still be opposed under trade mark law. Both clearances are needed.

Can a medicine have different names in different EU countries?

For centralised products, only in exceptional cases relating to trade mark law, where the Commission may accept a second name for a Member State. For products authorised nationally or through mutual recognition or the decentralised procedure, each Member State approves the name under its own guidance, so names can differ between countries. A single name has to be acceptable to every agency concerned.

Screen the shortlist before you file

Name Checker screens up to ten candidate names against EU and national registers, trade marks, WHO INN stems and the EEA languages, and shows the rule and the source behind every finding.

Check your candidate names

Enter the names, the INN and where you will file. The report ranks the names side by side and can be downloaded as a Word document.

Try for free

Book a naming walkthrough

30 minutes on your shortlist: how the screen reads the registers and rulebooks, and what the report gives your regulatory team and trade mark counsel.

Book a demo